Company news
MedinCell SA news in 2026
MedinCell SA's news releases, calls and decks from 2026, newest first.
Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)
October 13, 2026
Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan
October 12, 2026
Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2: 45pm
October 8, 2026
Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)
October 8, 2026
Medincell prolongation exceptionnelle de la période de vote par correspondance pour l’Assemblée Générale jusqu'à 15h00 aujourd'hui
September 29, 2026
Medincell Extends Remote Voting Deadline for its Annual General Meeting Until 3: 00 p.m. Today
September 30, 2026
Medincell to Participate in Upcoming Investor Conferences
September 9, 2026
Medincell: Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting
September 8, 2026
Medincell Appoints Edna Venneker, MD, as Chief Medical Officer
September 1, 2026
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
July 29, 2026
Medincell Continues to Strengthen and Renew Its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg
July 28, 2026
Medincell Aligns Debt Maturity With Its Expected Revenue Growth Trajectory
July 15, 2026
Medincell: Half-Year Liquidity Contract Statement
July 6, 2026
Medincell Reports FY 2025-26 Annual Results
June 16, 2026
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
May 28, 2026
Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June
May 26, 2026
Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year
April 29, 2026
Degroof Petercam Initiates Medincell’s Coverage with a "Buy" Recommendation
April 22, 2026
Leerink Partners Initiates Medincell’s Coverage with a "Outperform" Recommendation
April 21, 2026
Medincell to Host an Online R&D Day on Tuesday, May 12, 2026
April 16, 2026
EIB Waives its Right to Cash Settlement on Medincell Warrants
March 26, 2026
Medincell Announces Successful c. €48 Million Private Placement
March 6, 2026
Medincell Launches a Private Placement for International Institutional Investors
March 5, 2026
Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026
March 4, 2026
Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026
February 24, 2026
Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
February 20, 2026
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
February 20, 2026
Medincell’s ISS ESG Corporate Rating Upgraded
February 10, 2026
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)
January 28, 2026
Medincell: Half-year Liquidity Contract Statement
January 20, 2026
Medincell: Publication of the 2026 Financial Calendar
January 12, 2026
Decks in 2026
- Corporate Update (October 2026)
Corporate update · 17 slides · Oct 9, 2026